Document Detail


Pharmacotherapy of Lung Transplantation: An Overview.
MedLine Citation:
PMID:  23204148     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Lung transplantation has become a viable treatment therapy for end-stage lung disease patients. The most common etiologies of end-stage lung disease, which can require a transplant are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and pulmonary fibrosis (PF). Listing criteria are institution and program specific. Approximately 1500 lung transplants were performed in 2008; and at 5 years post transplant, one-half are expected to survive. The surgery itself is associated with various complications, including surgical, infectious, and mechanical. Immunosuppression is paramount to the management of these patients, the goal being prevention of T cell activation to prevent rejection of the new organ. The patients commonly receive an induction agent with a T cell depleting antibody and high-dose corticosteroids. Maintenance immunosuppression begins immediately after the surgery, consisting of a combination of a calcineurin inhibitor, antimetabolite, and corticosteroids. Side effect profiles from the various agents will determine the choice of agents, and patients may have modifications throughout the therapy. The role of the pharmacist spans the inpatient management of acute complications to medication selection, management of maintenance immunosuppression, as well as monitoring for adverse drug reactions and drug-drug interactions. A multidisciplinary collaborative approach must be taken to ensure the best outcomes for this patient population.
Authors:
Melissa L Thompson; Jeremy D Flynn; Timothy M Clifford
Related Documents :
15892978 - Single cell electrophoresis in determining cell death: potential for use in organ trans...
23352298 - Local allocation of lung donors results in transplanting lungs in lower priority transp...
7709458 - Successful extrarenal transplantation from non-heart-beating donors.
23313558 - Surfactant application in experimental lung transplantation.
19376388 - Simultaneous pancreas-kidney transplantation: evaluation of graft function, cholesterol...
18511408 - Characterization of long-term endogenous cardiac repair in children after heart transpl...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-2
Journal Detail:
Title:  Journal of pharmacy practice     Volume:  -     ISSN:  1531-1937     ISO Abbreviation:  J Pharm Pract     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8900945     Medline TA:  J Pharm Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes.
Next Document:  Banning tobacco sales in massachusetts' pharmacies.